For the quarter ending 2025-09-30, PASG had -$4,853K decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -32,539 | - |
| Depreciation and amortization | 181 | 370 |
| Sharebased compensation | 611 | 1,781 |
| Amortization of premium and discount on marketable securities, net | 0 | 129 |
| Impairment of long-lived assets | 2,637 | - |
| Other non-cash items | 0 | 14 |
| Prepaid expenses and other current assets, and other assets | 235 | 571 |
| Prepaid research and development | 33 | 66 |
| Non-refundable sublicense and transition services payments received | 2,500 | 1,515 |
| Right of use assets and operating lease liabilities | 122 | 215 |
| Accounts payable | 66 | 1,653 |
| Accrued expenses and other current liabilities | -72 | -2,634 |
| Net cash provided by (used in) operating activities | -4,853 | -20,177 |
| Sales or maturities of marketable securities | 0 | 39,046 |
| Sale of property and equipment and other assets | 0 | 1,170 |
| Net cash provided by (used in) investing activities | 0 | 40,216 |
| Proceeds from the issuance of common stock under employee stock purchase plan | 0 | 14 |
| Net cash provided by (used in) financing activities | 0 | 14 |
| Net increase (decrease) in cash and cash equivalents | -4,853 | 20,053 |
| Cash and cash equivalents at beginning of period | 37,573 | - |
| Cash and cash equivalents at end of period | 52,773 | - |
Passage BIO, Inc. (PASG)
Passage BIO, Inc. (PASG)